Table 3.
Overview of follow‐up visits, S‐100B tests, and FDG PET/CT scans
| Patient assessment | |
|---|---|
| Years of follow‐up, median (range) | 4.7 (0.7‐15.3) |
| S‐100B samples, N | 456 |
| Normal, n, % | 414 (90.8%) |
| Elevated, a n, % | 42 (9.2%) |
| Indication for FDG PET/CT scan, n, % | |
| Symptoms | 26 (62%) |
| Symptoms + elevated S‐100B | 3 (7.1%) |
| Elevated S‐100B | 10 (23.8%) |
| S‐100B level elevation ≥40% | 3 (7.1%) |
| Total FDG PET/CT scans, b N | 42 |
| Positive FDG PET/CT scans, n (%) | 30 (71.4%) |
| Negative FDG PET/CT scans, n (%) | 12 (28.6%) |
Abbreviations: FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed tomography.
a
All elevated S‐100B samples, including repeated measurements from a single patient in cases showing an S‐100B elevation of ≥40%.
b
One FDG PET/CT scan per patient; additional scans performed after one positive FDG PET/CT scan were not counted.